CRISPR THERAPEUTICS AG — Income Charts
8 quarters of history · ending 2025-12-31 · SEC EDGAR
Source:10-K · 10-Q
Revenue, Gross Profit, Operating Income & Net Income
Margin (%)
Operating Expenses
Income Breakdown
Revenue↓-97.6% -$35M
$864K
R&D↑+16.4% +$12M
$84M
D&A↑+16.9% +$819K
$6M
Operating Income↓-19.9% -$22M
$-132M
EBITDA↑+16.9% +$819K
$6M
Interest Expense
—
Other Income/Expense↑+4.7% +$1M
$26M
Pretax Income↓-24.4% -$21M
$-106M
Tax Provision↓-12.3% -$86K
$614K
Net Income↓-23.9% -$20M
$-106M
Operating Margin↑+3439.2pts
-14854.8%
Net Margin↑+2303.0pts
-11973.1%
Effective Tax Rate↑+0.4pts
-0.6%
ETR (Continuing Operations)↑+0.4pts
-0.6%
ETR Federal Statutory
11.9%
ETR State + Local (pp)
1.1%
ETR Foreign Differential (pp)
-1.0%
Operating Lease Cost↓-3.1% -$574K
$18M
Revenue YoY Variation↓-15.3pts
-97.6%
Income YoY Variation↓-36.7pts
-19.9%
Revenue QoQ Variation↓-5831.5pts
-2.8%
Income QoQ Variation↑+15.2pts
42.4%